Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome

NCT05819853 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help restore ovulation in females with polycystic ovary syndrome (PCOS) who are also obese.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 80 people Planned (estimated).

Who can join Ages 12–35 · female only

Timeline Started 2023-11 · est. completion 2028-06

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT05819853 ↗

Description as written by the study sponsor.

Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.

Treatments tested

Semaglutide Injectable Product (Wegovy and/or Ozempic) also known as Semaglutide (Wegovy and/or Ozempic) Drug

10 months of semaglutide, with dose escalation as recommended by manufacturer. Maximum dose used will be 1.7mg

Main thing measured	Change in ovulation frequency before and after semaglutide in females with PCOS
Sponsor	University of Colorado, Denver
Conditions studied	PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05819853 ↗